成人先天性心脏病中 HFpEF 的调查
本项回顾性多中心队列研究纳入丹麦东部 4507 例双心室生理、体循环左心室的成人先天性心脏病(ACHD)患者。结果显示 HFpEF 患病率为 13%,且在不同 ACHD 严重程度中均较高。HFpEF 患者年龄更大、合并症更多,心血管住院率几乎升高 5 倍,但仅 4.0% 有心衰诊断、5.8% 使用 SGLT2 抑制剂。
要点
- ACHD 患者中 HFpEF 的患病率高达 13%,与 ACHD 严重程度无关。
- ACHD-HFpEF 患者的心血管住院率几乎为正常心室功能者的 5 倍。
- 该人群的 HFpEF 临床诊断率与 SGLT2 抑制剂使用率均极低。
核心结论
- 在成人先天性心脏病患者中,无论 ACHD 严重程度如何,HFpEF 患病率均较高(13%),并与心血管住院率几乎升高 5 倍相关。
- 尽管心血管住院负担重,但该人群中仅极少数被诊断为心衰或接受 SGLT2 抑制剂治疗。
研究设计与样本
- 回顾性多中心队列研究,利用电子病历纳入丹麦东部 ACHD 中心随访的 4507 例患者。
- 入选标准为双心室心脏生理且体循环左心室,HFpEF 定义为 LVEF≥50% 且使用利尿剂,同时伴 NT-proBNP 升高和/或 HFpEF 超声心动图征象。
主要发现
- 4507 例 ACHD 患者中 86% 的 LVEF 保留,HFpEF 检出率为 13%;在轻度、中度、重度 ACHD 中患病率分别为 13%、12% 和 18%。
- 与左心室功能正常者相比,HFpEF 患者中位年龄更高 [60 岁 (IQR 47-70) vs 41 岁 (IQR 29-56),P<.001]。
- HFpEF 患者的糖尿病年龄校正比值比 15.60(95%CI 12.39-19.70)、肥胖 1.48(95%CI 1.17-1.87)、房颤 4.58(95%CI 2.22-9.88)。
- HFpEF 患者的心血管住院率几乎升高 5 倍 [发病率比 4.6(95%CI 4.2-5.1),P<.0001]。
- 仅 4.0% 的 HFpEF 患者有心衰诊断,5.8% 接受 SGLT2 抑制剂治疗。
关键数值与推荐
- HFpEF 诊断需同时满足:LVEF≥50%、使用利尿剂,且 NT-proBNP 升高和/或存在 HFpEF 相关超声心动图征象。
临床怎么用
- 在 ACHD 人群各严重层级中均应主动筛查 HFpEF,尤其关注高龄、糖尿病、肥胖及房颤患者。
- 对确诊 ACHD-HFpEF 患者,应考虑启动 SGLT2 抑制剂治疗以减轻高住院负担。
局限性
- 仅纳入丹麦东部双心室生理、体循环左心室的 ACHD 患者,结论不宜直接外推至其他病变类型。
- HFpEF 定义依赖利尿剂使用联合生物标志物或超声标准,可能低估或误判部分患者。
- SGLT2 抑制剂使用数据可能受限于研究时期及当时指南推荐的普及程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in the general population, but the prevalence among adults with congenital heart disease (ACHD) is not well described. The study aimed to determine the prevalence, characteristics, and hospitalization burden of HFpEF among ACHD patients. METHODS: Using the electronic medical files, a retrospective, multicentre cohort study was conducted including 4507 ACHD patients with biventricular heart physiology and systemic left ventricle followed at the ACHD centres in Eastern Denmark. Heart failure with preserved ejection fraction was defined as preserved left ventricular ejection fraction (LVEF ≥ 50%) with diuretics use, combined with elevated N-terminal pro-B-type natriuretic peptide and/or echocardiographic signs of HFpEF. RESULTS: Among 4507 ACHD patients, 86% had a preserved LVEF. Heart failure with preserved ejection fraction was identified in 13%, with high prevalence across all ACHD severities (13%, 12%, and 18% in mild, moderate, and severe). Compared with patients with normal left ventricular function, HFpEF patients were older {median age: 60 [interquartile range (IQR) 47-70] vs 41 [IQR 29-56] years, P < .001}, had more comorbidities {age-adjusted odds ratio for diabetes: 15.60 [95% confidence interval (CI) 12.39-19.70]; obesity: 1.48 [95% CI 1.17-1.87], and atrial fibrillation 4.58 [95% CI 2.22-9.88]}, and experienced almost five-fold higher rate of cardiovascular hospitalization [incidence rate ratio 4.6 (95% CI 4.2-5.1), P < .0001]. Despite this, only 4.0% had a heart failure diagnosis, and 5.8% were treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor. CONCLUSIONS: Heart failure with preserved ejection fraction is highly prevalent among ACHD patients, regardless of ACHD severity. It is associated with an increased burden of cardiovascular risk factors and hospitalizations. Despite this, only a minority received SGLT2 inhibitors. These findings emphasize the need for increased awareness of HFpEF in the ACHD population.
引用
- Maegaard Eriksen, Lim, Thuraiaiyah, et al. Heart failure with preserved ejection fraction in adults with congenital heart disease. Eur Heart J. 2026. PMID: 41614664. doi:10.1093/eurheartj/ehag017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。